Alector, Inc. (NASDAQ:ALEC – Free Report) – Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Alector in a research report issued to clients and investors on Wednesday, October 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research report on Saturday, September 27th. Alector Stock PerformanceShares of Alector stock opened at $3.32 on Friday. Acadian Asset Management LLC raised its holdings in shares of Alector by 50.7% in the 2nd quarter. Alector Company Profile(Get Free Report)Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.